Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the appointment of Marc Grasso, M.D., as its Chief Financial Officer (CFO). Dr. Grasso brings more than 25 years of public company, capital markets, and investment banking management experience to the role. He succeeds Ryan Jones, MBA, who will move to a strategic advisor role to ensure a seamless transition. 

“We are excited to welcome Marc, an accomplished life-sciences leader with a proven track record working in capital markets and driving financial discipline and operational execution in maturing public companies,” said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics.  “As we continue to accelerate our clinical development and commercialization efforts, Marc’s leadership will be instrumental in supporting our next phase of growth and advancing our mission to bring the transformative potential of CAR T-cell therapy to patients with autoimmune diseases. On behalf of the Kyverna leadership team, I’d also like to thank Ryan, one of Kyverna’s first employees, for the significant contributions he has made throughout his tenure with the Company.”   

“I am thrilled to join Kyverna at this dynamic time and help accelerate the next critical phase of growth for the Company,” said Dr. Grasso.  “I look forward to leveraging my experience to contribute to Kyverna’s goal of bringing the first CAR T-cell therapy for autoimmune disease to market and drive business and financial strategies that support the Company’s mission.”